Submitted by Anonymous (not verified) on 24 June 2025 - 16:26
Opinion/decision on a Paediatric investigation plan (PIP): Ebglyss, Lebrikizumab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Respiratory, thoracic and mediastinal disorders, PIP number: P/0212/2024
Source: